Electroconvulsive Therapy in Clozapine-resistant Schizophrenia
Not Applicable
- Conditions
- SchizophreniaSchizoaffective Disorder
- Interventions
- Device: electroconvulsive therapy
- Registration Number
- NCT02159001
- Lead Sponsor
- Niuvanniemi Hospital
- Brief Summary
Electroconvulsive therapy (ECT) is one of the oldest neuromodulation treatments still used in psychiatry. Only case reports and open label non-randomized studies have been published of ECT in clozapine-resistant schizophrenia patients. The purpose of this trial is to study the efficacy and cognitive effects of add-on ECT treatment (10-course) in schizophrenia patients taking clozapine.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- diagnosis of schizophrenia or schizoaffective disorder
- treatment-resistant to clozapine
- age 18 - 64 years
- capacity and willingness to give informed consent
Exclusion Criteria
- serious somatic illness
- progressive neurological illness, recent brain damage or sequela of serious brain damage
- ECT less than 3 months prior to this trial
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description ECT after 4 weeks period. electroconvulsive therapy This group receives electroconvulsive therapy treatment after 4 weeks waiting period. ECT treatment right after recruitment electroconvulsive therapy This group receives electroconvulsive therapy treatment right after they are recruited.
- Primary Outcome Measures
Name Time Method Positive and Negative Symptom Scale 2 days Positive and Negative Symptom Scale (PANSS) is assessed two days after ECT course
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Niuvanniemi Hospital
🇫🇮Kuopio, Finland